← Leaderboards
Nanjoo Suh
Rutgers The St Univ Of Nj New Brunswick
$4,550,136
Attributed
$4,552,636
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $632.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,552,636 · 9
By mechanism
R01$3,431,793 · 3
R03$624,000 · 4
K22$491,843 · 1
R13$5,000 · 1
Top collaborators
- John M Pezzuto1 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCell LineMalignant Breast NeoplasmAnimal ModelReceptor SignalingMalignant NeoplasmsPreventionBreast Cancer ModelIn VitroCell ProliferationMolecularSignal PathwayMammary TumorigenesisCancer PreventionBreastAffectBreast Cancer CellSignal TransductionStagingNeoplasm MetastasisPre-ClinicalTissuesDietComplex
Grant awards (25)
Influence of environmental endocrine disruptors and carcinogenesis$78,500
R03 · FY2025 · ES · contact PI
Influence of environmental endocrine disruptors and carcinogenesis$78,500
R03 · FY2024 · ES · contact PI
A novel strategy targeting TP63 for breast cancer prevention$78,500
R03 · FY2023 · CA · contact PI
A novel strategy targeting TP63 for breast cancer prevention$78,500
R03 · FY2022 · CA · contact PI
Prevention of estrogen-mediated mammary carcinogenesis by mixtures of tocopherols$385,250
R01 · FY2016 · AT · contact PI
Prevention of estrogen-mediated mammary carcinogenesis by mixtures of tocopherols$373,757
R01 · FY2015 · AT · contact PI
Prevention of estrogen-mediated mammary carcinogenesis by mixtures of tocopherols$376,489
R01 · FY2014 · AT · contact PI
Prevention of estrogen-mediated mammary carcinogenesis by mixtures of tocopherols$379,212
R01 · FY2013 · AT · contact PI
Prevention of estrogen-mediated mammary carcinogenesis by mixtures of tocopherols$391,003
R01 · FY2012 · AT · contact PI
Inhibition of breast cancer progression by vitamin D analogs and triterpenoids$241,812
R01 · FY2012 · CA · contact PI
Inhibition of breast cancer progression by vitamin D analogs and triterpenoids$242,016
R01 · FY2011 · CA · contact PI
Natural Products in the Prevention of Cancer$5,000
R13 · FY2011 · CA · contact PI
Inhibition of breast cancer progression by vitamin D analogs and triterpenoids$249,703
R01 · FY2010 · CA · contact PI
Tocopherol-mediated inhibition of breast carcinogenesis$77,250
R03 · FY2010 · CA · contact PI
Inhibition of breast cancer progression by vitamin D analogs and triterpenoids$249,901
R01 · FY2009 · CA · contact PI
Tocopherol-mediated inhibition of breast carcinogenesis$77,250
R03 · FY2009 · CA · contact PI
Inhibition of breast cancer progression by vitamin D analogs and triterpenoids$17,150
R01 · FY2009 · CA · contact PI
Inhibition of breast cancer progression by vitamin D analogs and triterpenoids$250,092
R01 · FY2008 · CA · contact PI
COX-2 Inhibitor and N-3PUFA in Colon Cancer Prevention$275,408
R01 · FY2007 · CA · contact PI
Mechanism Based Chemoprevention of Cancer$158,789
K22 · FY2005 · CA
Chemoprevention of cancer by nuclear receptor ligands$77,750
R03 · FY2005 · CA
Mechanism Based Chemoprevention of Cancer$158,789
K22 · FY2004 · CA
Chemoprevention of cancer by nuclear receptor ligands$77,750
R03 · FY2004 · CA
Mechanism Based Chemoprevention of Cancer$151,098
K22 · FY2003 · CA
Mechanism Based Chemoprevention of Cancer$23,167
K22 · FY2003 · CA